pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Phase 3

Sep 27, 2023

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Sep 27, 2023

Venatorx Pharmaceuticals to Present at IDWeek 2023

Sep 26, 2023

Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer’s Disease Day, and BIO Investor Forum

Sep 20, 2023

AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery USA - English APAC - English

Aug 15, 2023

Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults

Aug 10, 2023

AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder USA - English APAC - English

Aug 3, 2023

Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)

Jul 24, 2023

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Jul 24, 2023

CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC

Jul 20, 2023

Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome

Jul 20, 2023

Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Pachyonychia Congenita

Jul 18, 2023

Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder

Jul 11, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam

Jun 7, 2023

Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide, a PTHR1 Agonist Entering Phase 3 for the Treatment of Hypoparathyroidism, in Chicago on June 16, 2023

Jun 7, 2023

Amolyt Pharma organise le 16 juin 2023 à Chicago un événement hybride avec des leaders d'opinion sur l'énéboparatide, un agoniste du PTHR1 entrant en phase 3 pour le traitement de l'hypoparathyroïdie

May 31, 2023

RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

May 22, 2023

Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment using ASP-1929 for Recurrent Head and Neck Cancer in India

May 18, 2023

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

May 17, 2023

NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

May 15, 2023

Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023

May 12, 2023

Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference

May 9, 2023

PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

May 8, 2023

Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

May 4, 2023

Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023

May 2, 2023

Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism following Positive End of Phase 2 Meeting with FDA

May 2, 2023

Amolyt Pharma annonce l'essai clinique de phase 3 de l'énéboparatide dans le traitement de l'hypoparathyroïdie après des interactions positives de fin de Phase 2 avec la FDA

Apr 25, 2023

Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington’s Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual Meeting

Apr 25, 2023

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Apr 25, 2023

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Apr 23, 2023

Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting

Apr 20, 2023

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia

Apr 20, 2023

Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Society of Cataract and Refractive Surgery and Association for Research in Vision and Ophthalmology Annual Meetings

Apr 19, 2023

CORRECTING and REPLACING Direct Biologics Reports Compelling Data as ExoFlo™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects

Apr 18, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

Apr 17, 2023

AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery USA - English APAC - English

Apr 17, 2023

AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery APAC - English USA - English

Apr 12, 2023

Novaliq Announces Publication of Second Pivotal Phase 3 Trial Data on CyclASol 0.1% (Cyclosporine Ophthalmic Solution) in JAMA Ophthalmology

Apr 4, 2023

Direct Biologics Announces FDA Authorization to Expand Ongoing Phase 3 Clinical Study of ExoFlo™ to All-Cause Moderate-to-Severe ARDS

Mar 28, 2023

Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease

Mar 22, 2023

Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia

Mar 22, 2023

Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease

Mar 22, 2023

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

Mar 14, 2023

Direct Biologics Reports Compelling Results From Phase 2 Trial With ExoFlo™ in Hospitalized Patients With Respiratory Failure or Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19

Mar 9, 2023

AM-Pharma to Present Data From Phase 3 REVIVAL Study at Upcoming Scientific Conferences

Mar 9, 2023

Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy

Mar 7, 2023

LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies

Mar 2, 2023

Visus Therapeutics to Attend TD Cowen’s 43rd Annual Health Care Conference

Feb 21, 2023

Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies

Feb 15, 2023

Bryn Pharma UTULY™ Phase 3 Data accepted as Late-Breaker at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting

Jan 30, 2023

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China

Jan 5, 2023

First Participants Enrolled in the AriBio USA Phase 3 Registration Trial to Evaluate AR1001 in Early Alzheimer’s Disease

Jan 4, 2023

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Jan 3, 2023

Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)

Jan 3, 2023

Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Dec 19, 2022

Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial

Dec 10, 2022

Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th ASH Annual Meeting

Dec 6, 2022

Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease

Nov 30, 2022

Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis

Nov 22, 2022

Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease Conference

Nov 17, 2022

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

Nov 15, 2022

Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 14, 2022

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results USA - English USA - English USA - English

Nov 14, 2022

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results USA - English USA - English

Nov 14, 2022

Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma

Nov 14, 2022

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results India - English USA - English

Oct 26, 2022

Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines

Oct 20, 2022

AM-Pharma Provides Business Update and Outcome of Pre-planned Interim Futility Analysis of Phase 3 REVIVAL Study

Oct 14, 2022

SIFI fait état de résultats positifs détaillés et de nouvelles données obtenus dans le cadre de l'essai de phase 3 d'AKANTIOR chez les patients atteints de kératite à acanthamoeba lors de la réunion annuelle de l'American Academy of Ophthalmology à Chicago France - Français USA - English USA - English España - español Deutschland - Deutsch

Oct 13, 2022

SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR in Patients with Acanthamoeba Keratitis presented at the American Academy of Ophthalmology Annual Meeting in Chicago USA - English USA - English España - español France - Français Deutschland - Deutsch

Oct 13, 2022

SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR in Patients with Acanthamoeba Keratitis presented at the American Academy of Ophthalmology Annual Meeting in Chicago USA - English France - Français Deutschland - Deutsch

Oct 13, 2022

SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR in Patients with Acanthamoeba Keratitis presented at the American Academy of Ophthalmology Annual Meeting in Chicago USA - English USA - English USA - español USA - Français USA - Deutsch

Oct 6, 2022

TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions USA - English USA - English

Oct 6, 2022

Dundee Corporation Portfolio Holding, TauRx Pharmaceuticals Ltd., Announces Results from Phase 3 Study, LUCIDITY, and Proceeds with Regulatory Submissions

Oct 6, 2022

TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions USA - English India - English

Oct 5, 2022

Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority

Sep 27, 2022

Good Works II Acquisition Corp. Announces Letter of Intent for a Business Combination with Direct Biologics, LLC

Sep 21, 2022

Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

Sep 15, 2022

Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson's Disease and Movement Disorders

Sep 13, 2022

ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases

Sep 10, 2022

Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma

Sep 7, 2022

Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study

Aug 25, 2022

Mycovia Pharmaceuticals’ Phase 3 ultraVIOLET Study Evaluating the Efficacy and Safety of VIVJOA™ (oteseconazole) in Women with Recurrent Vulvovaginal Candidiasis (RVVC) Published in the American Journal of Obstetrics and Gynecology

Aug 25, 2022

Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022

Aug 2, 2022

Mycovia Pharmaceuticals Announces Presentation of Topline Results from Two Studies Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) at the 2022 IDSOG Annual Meeting

Aug 2, 2022

Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.

Jul 28, 2022

NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Jul 26, 2022

InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation

Jul 26, 2022

Alzheon to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ-801 (Valiltramiprosate) Oral Tablet at 2022 Alzheimer’s Association International Conference

Jul 26, 2022

Mycovia Pharmaceuticals Announces Publication of Positive Phase 3 Data Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) in NEJM Evidence

Jul 25, 2022

NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases

Jul 13, 2022

Newly Published Phase 3 Study in People with COVID-19 Shows SaNOtize Nitric Oxide Nasal Spray Reduced Viral Load by 99% within Two Days

Jul 13, 2022

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

Jul 12, 2022

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding

Jun 28, 2022

PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia

Jun 28, 2022

Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jun 28, 2022

Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)

Jun 27, 2022

Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Jun 22, 2022

BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury

Jun 2, 2022

Anji Pharma Provides Update on ANJ900 Pivotal Program

May 24, 2022

ZZ Biotech’s Stroke Drug Moves Closer to Pivotal Phase 3 Clinical Trial as the NIH Awards First Tranche of $30 Million Grant to the Keck School of Medicine of USC

May 11, 2022

Spine BioPharma Initiating U.S. Phase 3 Clinical Study

May 10, 2022

AMO Pharma Announces Additional Private Equity Investment Following Progress in Phase 3 Study in Congenital Myotonic Dystrophy

May 10, 2022

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

May 5, 2022

Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine

May 4, 2022

Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders

Apr 26, 2022

NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL (0.1% CYCLOSPORINE OPHTHALMIC SOLUTION) AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING

Apr 25, 2022

400 Patients Have Been Enrolled in AM-Pharma’s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-associated Acute Kidney Injury

Apr 25, 2022

Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation and Cellular Therapy ASTCT and CIBMTR Tandem Meetings

Apr 21, 2022

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Apr 14, 2022

Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio

Apr 14, 2022

Alzheon Appoints Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development and Medical Affairs, and Erwan de Naurois as Vice President of Finance

Apr 13, 2022

PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host and Microbe and Highlights Planned Presentations of Phase 2 VE303 Results

Apr 13, 2022

Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host and Microbe and Highlights Planned Presentations of Phase 2 VE303 Results

Apr 5, 2022

Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting

Mar 29, 2022

Angiocrine Bioscience Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of AB-205 in Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) and Completion of Series B Financing

Mar 22, 2022

Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia

Mar 22, 2022

Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study

Mar 15, 2022

Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate USA - English USA - English

Mar 15, 2022

Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate

Mar 11, 2022

The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue), Published in JAMA Oncology

Mar 10, 2022

Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI

Mar 10, 2022

Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial

Mar 8, 2022

Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences

Mar 2, 2022

Innocoll Announces Positive Topline Results For XARACOLL (bupivacaine hydrochloride) implant in a Phase 3 Study to Support Expanded Use

Mar 2, 2022

SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations

Feb 25, 2022

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19

Feb 22, 2022

HighTide Therapeutics Announces End-of-Phase 2 Meeting with FDA and Agreement to Proceed to Phase 3 for HTD1801 for the Treatment of PSC

Feb 15, 2022

Laurent Pharmaceuticals Starts Phase 3 Study With Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

Feb 9, 2022

Phase 3 Clinical Trial Confirms SaNOtize’s Breakthrough Treatment is 99% Effective Against COVID-19; Receives Regulatory Approval in India

Feb 8, 2022

Alzheon Reports Industry-Leading Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

Feb 2, 2022

Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor

Jan 27, 2022

Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment

Jan 26, 2022

Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling Phase 3 Studies for Vocacapsaicin

Jan 24, 2022

Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients

Jan 24, 2022

SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19

Jan 19, 2022

Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

Jan 5, 2022

Alzheon to Present at H.C. Wainwright Bioconnect Conference on January 10, 2022

Jan 4, 2022

UNION therapeutics announces enrollment of first patient in the IASOS Phase 2b study of oral orismilast in psoriasis patients

Jan 4, 2022

NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) and/or Established Atherosclerotic Cardiovascular Disease (ASCVD)

Dec 22, 2021

AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy

Dec 21, 2021

Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol in Dry Eye Disease

Dec 20, 2021

CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Dec 17, 2021

Freya Pharma Solutions to acquire all IP from Emotional Brain, giving opportunities to further examine pharmaceutical therapies for Female Sexual Interest/Arousal Disorder in a double blind, randomized phase 3 trial

Dec 16, 2021

Medicago submits Phase 3 data to Health Canada for its plant-based COVID-19 vaccine candidate

Dec 16, 2021

Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)

Dec 11, 2021

Positive Clinical Results from More than 100 Patients Treated with Orca Bio’s Lead Investigational High Precision Cell Therapy Presented at 63rd ASH Annual Meeting

Dec 7, 2021

Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate

Nov 30, 2021

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia

Nov 29, 2021

Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study

Nov 9, 2021

Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 4, 2021

Vascular Therapies Announces Presentation of Phase 3 Clinical Trial Results at the American Society of Nephrology Meeting

Nov 4, 2021

Amylyx Pharmaceuticals Announces Participants Dosed in the Global Phase 3 PHOENIX Study of AMX0035 in ALS

Nov 3, 2021

Mycovia Pharmaceuticals Announces Completion of Partner Jiangsu Hengrui Pharmaceuticals’ Phase 3 Clinical Study Evaluating Oteseconazole for Treatment of Acute Vulvovaginal Candidiasis (VVC) in China

Nov 2, 2021

Denovo Biopharma LLC Announces Multiple Presentations at Major Conferences

Nov 1, 2021

Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference

Oct 29, 2021

Significant ADHD Symptom Improvement with 30-Minute Onset and 13-Hour Duration of Efficacy Delivered by Once-Daily Corium Product AZSTARYS (serdexmethylphenidate and dexmethylphenidate) in Children Ages 6 to 12 Years

Oct 28, 2021

Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613 (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

Oct 28, 2021

Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Oct 21, 2021

Currax Pharmaceuticals Granted Type C Meeting with FDA Regarding its Phase 3 Study to Evaluate the Safety and Efficacy of CX-101

Oct 20, 2021

Prilenia and Huntington Study Group Announce Completion of Patient Enrollment Ahead of Schedule in Global Phase 3 PROOF-HD Huntington’s Disease Clinical Trial

Oct 12, 2021

CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Oct 6, 2021

Apexigen Announces First Patient Dosed in Phase 3 Pivotal Trial for BD0801, an Anti-VEGF Monoclonal Antibody, in Combination Therapy for Ovarian Cancer

Oct 4, 2021

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

Sep 29, 2021

Mycovia Pharmaceuticals Announces Presentations of its Supportive Phase 3 Clinical Study (ultraVIOLET) Evaluating the Safety and Efficacy of Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) and Susceptibility Testing Against Clinical Isolates at IDWeek 2021 Virtual Conference

Sep 24, 2021

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

Sep 14, 2021

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

Sep 13, 2021

Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021

Sep 8, 2021

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

Sep 1, 2021

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection

Aug 17, 2021

Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam

Aug 10, 2021

Novaliq Completes Enrollment of Second Phase 3 Study for CyclASol for the Treatment of Dry Eye Disease USA - English España - español Deutschland - Deutsch Deutschland - Deutsch USA - English France - Français

Aug 10, 2021

Novaliq Completes Enrollment of Second Phase 3 Study for CyclASol for the Treatment of Dry Eye Disease USA - English USA - Français USA - español USA - Deutsch USA - Français

Aug 10, 2021

Novaliq achève le recrutement de participants pour la deuxième étude de phase 3 sur CyclASol pour le traitement de la sécheresse oculaire USA - Français USA - español USA - Deutsch USA - English

Jul 29, 2021

Mycovia Pharmaceuticals Announces Presentation of Oteseconazole (VT-1161) Phase 3 Data Demonstrating Safety and Efficacy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) at the 2021 IDSOG Annual Meeting

Jul 28, 2021

Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Jul 28, 2021

Mycovia Pharmaceuticals Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Jul 28, 2021

NewAmsterdam Pharma Reports Positive Results from Phase 2 Study of Oral Obicetrapib Demonstrating Over 50% LDL-Lowering as an Adjunct to High-Intensity Statins

Jul 26, 2021

Da Volterra Announces First Patient Randomized in Phase 3 Clinical Trial Evaluating the Gut Microbiome Protector DAV132 in Patients with Hematologic Malignancies

Jul 21, 2021

Vedanta Biosciences Completes $68 Million Series D Financing

Jul 21, 2021

PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

Jul 20, 2021

KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer's Disease

Jul 8, 2021

Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves 50% Enrollment

Jul 1, 2021

Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Jun 23, 2021

Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease

Jun 21, 2021

Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company

Jun 17, 2021

OncoNano Medicine Raises ~$50 Million in Series B Financing

Jun 11, 2021

OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function

Jun 10, 2021

Anji Pharma Launches Phase 3 Trial for ANJ900 to Treat Type 2 Diabetes Patients with Kidney Disease

Jun 9, 2021

InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team

Jun 4, 2021

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

Jun 4, 2021

Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ‑801 in Patients with Early Alzheimer’s Disease

Jun 1, 2021

Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

May 20, 2021

Medeor Therapeutics to Provide Interim Results of Phase 3 Mercury Study of MDR-101 Cell Therapy in Living Donor Kidney Transplants During Rapid Fire Oral Presentation at ATC Virtual Congress

May 13, 2021

Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO

May 12, 2021

Amylyx Pharmaceuticals Presents Trial Design of Global Phase 3 PHOENIX Study of AMX0035 in ALS at the European Network to Cure ALS (ENCALS) Meeting 2021

May 4, 2021

Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain

Apr 29, 2021

Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients

Apr 29, 2021

Novaliq annonce le recrutement de plus de 50 % des patients dans le cadre de l'essai de phase 3 ESSENCE-2 portant sur l'évaluation du CyclASol pour le traitement de la sécheresse oculaire France - Français España - español USA - English

Apr 29, 2021

Vascular Therapies Announces Clinical Results From Its Phase 3 Randomized Multicenter Clinical Trial

Apr 29, 2021

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19

Apr 28, 2021

Novaliq Announces More than 50% Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2 USA - English España - español France - Français

Apr 28, 2021

Novaliq Announces More than 50% Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2 USA - English USA - español USA - Français

Apr 22, 2021

ITM Raises EUR 90 M (USD 109 M) to Accelerate Precision Oncology Pipeline and Support Ongoing Phase 3 Clinical Program

Apr 14, 2021

Amylyx Pharmaceuticals Provides Global Regulatory Update on AMX0035 for ALS

Apr 14, 2021

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll (bupivacaine hydrochloride) Implant

Apr 14, 2021

Romark Announces Initial Results Of Phase 3 Clinical Trial Of NT-300 Tablets For The Treatment Of COVID-19

Mar 30, 2021

Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma

Mar 30, 2021

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Mar 30, 2021

HUYABIO INTERNATIONAL ANNOUNCES GLOBAL CLINICAL TRIAL COLLABORATION WITH BRISTOL MYERS SQUIBB IN MELANOMA

Mar 25, 2021

Apnimed Closes Series B Financing to Advance Once-Daily Oral Medication for Obstructive Sleep Apnea (OSA)

Mar 16, 2021

Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate

Mar 9, 2021

Alzheon to Present at H.C. Wainwright Global Life Sciences Conference on March 9, 2021

Mar 4, 2021

Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients

Mar 2, 2021

Orbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study

Feb 24, 2021

Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit

Feb 8, 2021

jCyte Announces Promotion of Dr. Shannon Blalock to Chief Executive Officer

Jan 28, 2021

Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease

Jan 19, 2021

Apnimed Announces First Patient Dosed in a Second Phase 2 Clinical Trial with AD109, a Disease Modifying Candidate for Obstructive Sleep Apnea

Jan 14, 2021

NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program

Jan 6, 2021

Mycovia Pharmaceuticals Announces Positive Topline Results from its Third Phase 3 Clinical Trial (ultraVIOLET) of Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Dec 23, 2020

Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita

Dec 17, 2020

EUSA Pharma Announces First Patient Enrolled in a Randomised Phase 3 Clinical Trial Investigating Siltuximab in Hospitalised Patients with COVID-19- or Another Respiratory Virus Infection-Associated Acute Respiratory Distress Syndrome (ARDS)

Dec 9, 2020

Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease

Dec 9, 2020

Mycovia Pharmaceuticals Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis

Dec 8, 2020

Candel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments

Dec 8, 2020

Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol Topical Ophthalmic Solution for the Treatment of Dry Eye Disease

Dec 2, 2020

Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Phase 3 “ultraVIOLET Study” for Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)

Nov 20, 2020

DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neuro-oncology (SNO) Annual Meeting

Nov 18, 2020

AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021

Nov 17, 2020

Palladio Biosciences Announces First Patient Dosed With Lixivaptan in The ALERT Study, a Phase 3 Study of ADPKD Patients Previously Discontinued From Treatment With Tolvaptan Due to Liver Toxicity

Nov 12, 2020

Denovo Biopharma LLC's Phase 3 Pivotal ENGINE Study of DB102 (Enzastaurin) in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Is Fully Enrolled

Nov 12, 2020

Mycovia Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Nov 9, 2020

Impel Neuropharma Announces FDA Submission Of New Drug Application For INP104 For The Acute Treatment Of Migraine

Nov 9, 2020

Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer

Nov 3, 2020

LianBio Announces Clearance to Initiate the Phase 3 PROOF Trial of Infigratinib in Patients with Locally Advanced or Metastatic Unresectable Cholangiocarcinoma with FGFR2 Gene Fusions in China

Oct 28, 2020

Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

Oct 27, 2020

Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Oct 27, 2020

Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United States

Oct 22, 2020

Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer

Oct 21, 2020

Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Global Phase 3 “VIOLET Studies” for Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)

Oct 8, 2020

Impel NeuroPharma Presents Data From Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine At 2020 Migraine Trust Virtual Symposium

Oct 6, 2020

Talaris Therapeutics Closes $115 Million Series B Financing

Sep 28, 2020

BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region

Sep 14, 2020

Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Sep 11, 2020

Cancer Prevention Pharmaceuticals Announces NEJM Publication of Landmark Phase 3 Clinical Trial for Treatment of Familial Adenomatous Polyposis

Sep 11, 2020

Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma

Aug 20, 2020

Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease

Aug 11, 2020

Romark Initiates New Phase 3 Clinical Trial Of NT-300 For The Treatment Of COVID-19

Aug 6, 2020

Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Aug 3, 2020

AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database

Jul 22, 2020

Talaris Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients

Jul 21, 2020

Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Jul 2, 2020

EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome

Jul 1, 2020

PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections English English

Jun 15, 2020

Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting

Jun 10, 2020

Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine

May 23, 2020

Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

May 12, 2020

POINT Biopharma Announces Phase 3 Prostate Cancer Trial

May 7, 2020

Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613 (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models

May 6, 2020

PTC Therapeutics to Acquire Censa Pharmaceuticals

Apr 27, 2020

Romark Initiates Phase 3 Clinical Trials Of NT-300 For COVID-19

Apr 6, 2020

OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact in Patients With Primary Hyperoxaluria

Mar 24, 2020

Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Mar 3, 2020

EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance

Feb 27, 2020

PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Sternal Wound Infection Post-cardiac Surgery

Feb 27, 2020

PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Sternal Wound Infection Post-cardiac Surgery English English

Feb 25, 2020

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP for Complicated Urinary Tract Infections

Feb 20, 2020

Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)

Feb 11, 2020

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis

Feb 10, 2020

NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference

Jan 14, 2020

Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Jan 14, 2020

Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson’s Disease

Jan 7, 2020

Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning

Dec 18, 2019

Mycovia Pharmaceuticals Completes Enrollment in its Third Phase 3 Clinical Trial for VT-1161 (ultraVIOLET) in Patients with Recurrent Vulvovaginal Candidiasis

Dec 2, 2019

PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

Nov 13, 2019

Palvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita

Nov 12, 2019

Mycovia Pharmaceuticals Announces Early Completion of Enrollment for Global Phase 3 Clinical Trials for VT-1161 (VIOLET) for the Treatment of Recurrent Vulvovaginal Candidiasis

Nov 8, 2019

Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting

Nov 6, 2019

Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet

Nov 5, 2019

Palladio Biosciences Announces Presentations of ELiSA Phase 2 Study Results and Phase 3 Lixivaptan Clinical Program Design during the American Society of Nephrology Kidney Week 2019 Meeting

Nov 5, 2019

EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer

Oct 28, 2019

Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Oct 24, 2019

Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer

Oct 23, 2019

Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients

Oct 21, 2019

Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies

Oct 11, 2019

CORRECTING and REPLACING Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Disease

Oct 8, 2019

Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Sep 30, 2019

Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 and 1/2a Clinical Trials USA - English Nederland - Nederlands España - español

Sep 23, 2019

Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back

Sep 19, 2019

Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sep 19, 2019

Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sep 19, 2019

MicuRx Reports Positive Top-line Results of a China Phase 3 Clinical Trial for Novel Antibiotic Contezolid in Complicated Skin and Soft Tissue Infections

Sep 17, 2019

Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain

Sep 17, 2019

Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

Sep 13, 2019

Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor

Sep 5, 2019

Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society

Sep 3, 2019

Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine

Aug 29, 2019

VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections

Aug 1, 2019

Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Aug 1, 2019

AZTherapies Completes Enrollment in COGNITE Pivotal Phase 3 Trial of ALZT-OP1 for the Treatment of Early Alzheimer’s Disease

Jul 24, 2019

Oyster Point Pharma Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Disease

Jul 18, 2019

Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration Techniques

Jul 18, 2019

Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

Jul 10, 2019

Impel NeuroPharma to Present Data From INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society

Jul 9, 2019

Mirum Pharmaceuticals Initiates Phase 3 Clinical Trial for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

Jun 24, 2019

Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region

Jun 20, 2019

Cancer Prevention Pharmaceuticals (CPP) Reports FAP Phase 3 Clinical Trial Results at Digestive Disease Week Conference

Jun 20, 2019

OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria USA - English España - español France - Français Deutschland - Deutsch

Jun 20, 2019

OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria USA - English USA - español USA - Français USA - Deutsch

Jun 20, 2019

OxThera initie la prolongation d'une étude de phase 3 sur Oxabact pour le traitement de l'hyperoxalurie primaire USA - English USA - Deutsch

Jun 19, 2019

Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis

Jun 18, 2019

Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight Therapeutics

Jun 11, 2019

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT

Jun 4, 2019

Braeburn Announces Publication of Phase 3 Study Results Showing Long-term Safety and Effectiveness of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder

Jun 4, 2019

Syntrix Pharmaceuticals Announces Publication of Positive Double-Blind Clinical Trials Showing Desmetramadol Has the Analgesic and Side Effect Profile of Tramadol Without Its Metabolic Liabilities

Jun 1, 2019

Rakuten Medical Releases Phase 2a Study Data during ASCO Annual Meeting Highlighting Positive Safety Profile and Clinically Meaningful Anti-tumor Activity

May 28, 2019

Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection

May 20, 2019

SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors

May 18, 2019

Talaris Therapeutics, Inc. Announces Promising Phase 2 Data of Novel, Allogeneic Cell Therapy in Living Donor Kidney Transplant Recipients

May 18, 2019

Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development

May 15, 2019

Rakuten Medical Highlights Upcoming Presentations and Activities During the ASCO Annual Meeting, May 31 - June 4, 2019 in Chicago

May 7, 2019

Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis

May 6, 2019

Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.

May 6, 2019

Curemark Presents Preschool Population Data from Phase 3 Blüm Autism Study

May 2, 2019

Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis

Apr 30, 2019

Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

Apr 29, 2019

OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation

Apr 15, 2019

Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

Apr 6, 2019

Positive Treatment Results for BRIXADI™ (buprenorphine) Extended-Release Injection in Fentanyl Positive Patients Presented at the 50th Conference of the American Society of Addiction Medicine

Apr 1, 2019

PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

Apr 1, 2019

Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium

Mar 26, 2019

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome

Mar 8, 2019

Cerebral Therapeutics Raises Series A Extension Financing to Advance Clinical-Stage Drug Device Combination Therapy to Phase 3 Readiness for Adult Refractory Epilepsy

Feb 28, 2019

Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis

Feb 27, 2019

Mycovia Pharmaceuticals Initiates Additional Phase 3 Clinical Study Evaluating VT-1161 for the Treatment of Vulvovaginal Candidiasis

Feb 26, 2019

Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Disease

Feb 23, 2019

Xynomic Pharma Doses First South Korean Patient in Phase 3 Renal Cell Carcinoma Trial and Hires Senior Executive Dr. Sophia Paspal to Head Regulatory Affairs and Quality Assurance

Feb 20, 2019

Peloton Therapeutics Secures $150 Million in Series E Financing

Jan 25, 2019

OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

Jan 17, 2019

Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium

Jan 17, 2019

AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease

Dec 11, 2018

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer

Dec 10, 2018

Cancer Prevention Pharmaceuticals Announces Last Patient Completes Phase 3 Trial Protocol of CPP-1X/sul for Familial Adenomatous Polyposis

Dec 5, 2018

Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

Nov 29, 2018

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Nov 19, 2018

Cancer Prevention Pharmaceuticals to Present at Piper Jaffray Healthcare Conference in NYC, November 28, 2018

Nov 16, 2018

Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica

Nov 12, 2018

PolyPid Announces FDA Clearance of Investigational New Drug Application (IND) to Commence Pivotal Phase 3 Clinical Trial of D-PLEX[100] for the Prevention of Sternal Wound Infection Post-Cardiac Surgery

Oct 23, 2018

Sirnaomics' siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma

Oct 23, 2018

Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies

Oct 23, 2018

Antiverse Raises Funding and Demonstrates Therapeutic Antibody Identification With AI-driven Drug Discovery Platform

Oct 9, 2018

AgeneBio Announces Two NIH Grant Awards to Advance its Therapeutic Pipeline to Combat Progression of Alzheimer's Disease

Sep 25, 2018

Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections

Sep 18, 2018

Braeburn Announces Positive Top-line Phase 3 Results for CAM2038 in Chronic Low Back Pain Patients Previously on Long-term Daily Opioid Therapy

Sep 6, 2018

Mycovia Pharmaceuticals Debuts with Initiation of Phase 3 Clinical Trials for Treatment of Recurrent Vulvovaginal Candidiasis

Sep 5, 2018

Advicenne Announces FDA Clearance of IND to Commence Pivotal Phase 3 Trial of ADV7103 for Distal Renal Tubular Acidosis

Aug 22, 2018

Impel Neuropharma Announces First Patient Dosed In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine Headache

Aug 8, 2018

Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes

Aug 2, 2018

Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

Jul 10, 2018

OxThera Updates on Phase 3 Study With Oxabact in Primary Hyperoxaluria USA - English France - Français Deutschland - Deutsch

Jul 10, 2018

OxThera Updates on Phase 3 Study With Oxabact in Primary Hyperoxaluria España - español Deutschland - Deutsch France - Français

Jun 22, 2018

Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine

May 16, 2018

PellePharm to Present Topical Patidegib and Skin Cancer Epidemiological Data at the 7th International Investigative Dermatology Meeting

May 14, 2018

Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine

Mar 26, 2018

Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to Treat Complicated Urinary Tract Infections (cUTI)

Feb 26, 2018

Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial

Feb 21, 2018

Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

Feb 8, 2018

Saghmos Therapeutics to Present at BIO CEO Conference in New York

Jan 22, 2018

Medeor Therapeutics Awarded $18.8 Million From the California Institute for Regenerative Medicine

Jan 9, 2018

Rebiotix Highlights 2017 Achievements and 2018 Objectives

Jan 4, 2018

PellePharm Appoints Sanuj K. Ravindran, M.D., as President and Chief Executive Officer

Jan 4, 2018

RDD Pharma Completes Enrollment in European Phase 3 Clinical Trial for Chronic Anal Fissure

Jan 4, 2018

Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities

Jan 2, 2018

Centrexion Therapeutics Raises $67 Million; Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018

Dec 19, 2017

Avillion Announces US Approval of Pfizer's BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

Dec 12, 2017

Espero BioPharma Provides Corporate Update and 2018 Objectives

Dec 6, 2017

Neumentum Raises $6 Million in Series A Funding to Develop Non-opioid Pain Products and Requests Type B Meeting with FDA

Dec 4, 2017

Atox Bio Closes $30 Million Investment

Nov 21, 2017

Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK-002 for the Treatment of Myopia in Children

Nov 20, 2017

FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to PellePharm for Topical Patidegib in Gorlin Syndrome

Nov 9, 2017

Vascular Therapies Announces Preliminary Results from its Phase 3 AV Fistula Study

Nov 2, 2017

Alzheon ALZ-801 Data Presented in Oral Session at CTAD on Role of Amyloid Oligomers in Alzheimer’s Disease

Nov 1, 2017

Symic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease

Oct 24, 2017

FDA Grants Fast Track Designation to Alzheon’s ALZ-801 Development Program for the Treatment of Alzheimer’s Disease

Oct 24, 2017

Alzheon Publishes Clinical Results that Demonstrate Safety Profile and Efficacy Potential of ALZ-801 as an Orally-Available Precision Medicine to Treat Alzheimer’s Disease

Oct 24, 2017

Denovo Biopharma Receives FDA's Permission to Proceed a Phase 3 Clinical Trial with DB102 (Enzastaurin) In the First Line Treatment of High Risk DLBCL

Oct 12, 2017

Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief Development Officer

Oct 12, 2017

Alzheon to Make Presentations on ALZ-801 and Its Anti-Oligomer Mechanism at the 10th Clinical Trials on Alzheimer’s Disease Congress

Oct 10, 2017

Generon Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in Chemotherapy-Induced Neutropenia

Sep 25, 2017

Curemark Completes Enrollment for its Phase 3 Clinical Trial for Children with Autism - The Blüm Study

Sep 19, 2017

AgeneBio Receives NIH Grant to Initiate Phase 3 HOPE4MCI Trial to Treat MCI Due to Alzheimer's Disease

Sep 11, 2017

Cancer Prevention Pharmaceuticals Receives $9.5 Million in Additional Funding from Sucampo Following Phase 3 Trial Progress

Sep 6, 2017

Rebiotix Appoints Edward S. Burd, Ph.D., to Head of Regulatory Affairs

Aug 7, 2017

Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection

Aug 1, 2017

Milestone Pharmaceuticals Closes $55 Million Series C Financing

Jul 31, 2017

PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas and Third Closing of a $20 Million Series B Financing

Jun 22, 2017

Alzheon Publishes New Analyses Showing Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease; Clinical Effects Suggest Disease Modification and Align with Beta Amyloid Oligomer Formation

Jun 12, 2017

Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients

May 25, 2017

Alzheon Scientists Discover Novel Therapeutic Mechanism of Inhibition of Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease Pathogenesis

May 23, 2017

Atox Bio's Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned

May 22, 2017

Symic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update

May 11, 2017

Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia

May 4, 2017

Rebiotix's Phase 3 ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017

May 2, 2017

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038

May 2, 2017

Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Phase 3 Safety Study of CAM2038

Apr 26, 2017

Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia

Mar 7, 2017

Trevi Therapeutics Names Michael Heffernan to Its Board of Directors

Feb 16, 2017

Denovo Biopharma plans to launch a Global Phase 3 Trial of DB102 (Enzastaurin) in Diffuse Large B-cell Lymphoma

Dec 9, 2016

Alzheon Presents Analyses from Phase 3 Clinical Studies Showing Largest Clinical Effects of Tramiprosate, the Active Molecule of ALZ-801, in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease

Dec 5, 2016

Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Nov 29, 2016

Emmaus Life Sciences Receives Notice of FDA PDUFA Date for Investigational L-glutamine Treatment for Sickle Cell Disease

Nov 14, 2016

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction

Nov 14, 2016

Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine for Treatment of Opioid Addiction

Nov 3, 2016

Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections

Nov 3, 2016

Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA and NDA Submission for XARACOLL

Oct 24, 2016

Alzheon Publishes New Analyses from Phase 3 Studies Showing Clinical Benefit of Tramiprosate in Alzheimer’s Patients Who Are Carriers of APOE4, the Major Genetic Risk Factor in up to 65 Percent of Alzheimer’s Patients

Oct 20, 2016

MicuRx Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA

Oct 17, 2016

Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology

Sep 30, 2016

Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for Treatment of Chronic Low Back Pain

Sep 30, 2016

Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for treatment of Chronic Low Back Pain

Sep 26, 2016

MicuRx Closes $55 Million Series C Financing to Support Development of Next-Generation Antibiotic MRX-I

Sep 1, 2016

Long Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial

Jul 27, 2016

TauRx Reports First Phase 3 Results for LMTX®

Jul 27, 2016

TauRx Reports First Phase 3 Results for LMTX

Jul 25, 2016

Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer's Patients with APOE4/4 Homozygous Genotype

Jun 29, 2016

Xcovery Announces Initiation of Phase 3 Trial of X-396 in ALK+ Non-Small Cell Lung Cancer

Jun 23, 2016

Innocoll Holdings plc Announces the Completion of Enrollment in Two Pivotal Phase 3 Clinical Trials of COGENZIA for the Treatment of Diabetic Foot Infections

Jun 17, 2016

Orbus Therapeutics Granted Orphan Drug Designation by European Medicines Agency for Late-Stage Brain Cancer Drug

May 25, 2016

Innocoll Announces XARACOLL (bupivacaine-collagen bioresorbable implant) Meets Primary Endpoint in Both Pivotal Phase 3 Trials in Postoperative Pain Relief

May 24, 2016

Innocoll to Host Live Webcast on Top-Line Results from Two Pivotal Phase 3 Trials of XARACOLL (bupivacaine-collagen bioresorbable implant) in Postoperative Pain Relief

May 18, 2016

RDD Pharma Announces First Patient Dosed in Phase 3 Clinical Trial for Chronic Anal Fissure

May 17, 2016

Clarus Therapeutics Initiates Phase 3 Clinical Trial of Oral Testosterone Replacement Therapy

May 6, 2016

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

Apr 8, 2016

MedDay Secures €34 Million ($38.5M) New Funding

Apr 5, 2016

Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence

Apr 4, 2016

Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis

Mar 11, 2016

Alzheon Announces Efficacy Analyses of Prior Tramiprosate Phase 3 Studies Showing Clinically Meaningful Benefits on Key Clinical Endpoints in Alzheimer’s Disease Patients with APOE4 Genotype

Dec 30, 2015

Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-acting Treatment for Opioid Dependence

Dec 30, 2015

Braeburn Pharmaceuticals and Camurus enroll first patient in a phase 3 efficacy trial of long-acting treatment for opioid dependence

Dec 15, 2015

Braeburn Pharmaceuticals and Camurus announce start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence

Dec 15, 2015

Camurus AB: Braeburn Pharmaceuticals and Camurus Announces Start of Phase 3 Trial of Long-Acting Buprenorphine Treatments for Opioid Dependence

Dec 15, 2015

Braeburn Pharmaceuticals and Camurus announces start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence

Dec 8, 2015

AgeneBio Appoints Richard Mohs, PhD, Vice President of Clinical Development

Dec 7, 2015

Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)

Nov 6, 2015

Alzheon Announces Initiation of Clinical Studies with ALZ-801 Bridging to Pivotal Phase 3 Study in Alzheimer’s Disease

Nov 6, 2015

Alzheon Announces Efficacy Outcomes from Two Prior Tramiprosate Phase 3 Studies

Nov 6, 2015

AgeneBio Presents Pharmacokinetic Profile of Proprietary, Extended-Release, Once-a-Day AGB101 Formulation at 8th Clinical Trials on Alzheimer's Disease

Oct 29, 2015

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints

Oct 27, 2015

Alzheon to Present Late-Breaking Presentation at 8th Clinical Trials on Alzheimer’s Disease Congress

Oct 22, 2015

AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer's Disease

Oct 8, 2015

TauRx Completes US$135m Financing Round to Support Phase 3 Clinical Trials Program in Alzheimer's and Frontotemporal Dementia

Oct 6, 2015

Emmaus Life Sciences to Present Abstract of Completed Phase 3 Sickle Cell Disease Trial at 9th Annual Sickle Cell and Thalassaemia Advanced Conference in London

Sep 16, 2015

Intarcia Presents Results From Two Successful Phase 3 Trials For ITCA 650, Its Investigational Therapy In Type 2 Diabetes, At 51st EASD

Sep 15, 2015

NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia

Sep 8, 2015

Neurimmune Receives Major Development Milestone Upon Initiation of Global Phase 3 Studies With Aducanumab for Early Alzheimer's Disease

Aug 20, 2015

Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board

Aug 18, 2015

Intarcia Announces New Top-Line Phase 3 Results For Investigational Therapy ITCA 650 In Type 2 Diabetes

Jul 1, 2015

CereSpir Incorporated Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jun 8, 2015

Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction

Jun 8, 2015

Intarcia Announces Presentations At ADA Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 -- A GLP-1 RA For Type 2 Diabetes

Jun 3, 2015

Intarcia To Announce Key ITCA 650 Phase 3 Findings And Other Data Presentations At Upcoming 75th Scientific Sessions of the American Diabetes Association In Boston

Jun 2, 2015

Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million

May 15, 2015

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-1 Phase 3 Study for the Treatment of Diabetic Foot Infection

May 1, 2015

Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments

Apr 28, 2015

Actavis and Medicines360 Announce Publication of ACCESS IUS Efficacy and Safety Study of LILETTA™ (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception

Apr 27, 2015

Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation

Apr 20, 2015

Icon Bioscience Announces Pivotal Phase 3 Clinical Data Demonstrates Exceptional Efficacy of IBI-10090 in Reducing Inflammation Associated with Cataract Surgery

Apr 6, 2015

Charleston Laboratories, Inc. Completes Patient Enrollment in a Phase 3 Study of Lead Product, CL-108

Apr 6, 2015

Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery

Apr 1, 2015

Pivotal Pharmacokinetic Study of Innocoll's XaraColl(R) Supports Use of 300 mg Dose for Phase 3 Clinical Studies in Post-Operative Pain

Mar 20, 2015

Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease

Nov 24, 2014

Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Trial Data At 56th American Society Of Hematology Annual Meeting

Nov 20, 2014

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Initiate Two Phase 3 Clinical Trials on Charleston's Lead Product, CL-108

Oct 6, 2014

Icon Bioscience Reports Last Patient Out in Its Phase 3 Study of IBI-10090 as a Dropless, Sustained-Released Therapeutic for Inflammation Associated with Cataract Surgery

Oct 1, 2014

Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results

Sep 19, 2014

Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes

Sep 11, 2014

Intarcia Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q

Jun 30, 2014

Icon Bioscience Announces Early Completion of Patient Enrollment in Its Phase 3 Study of IBI-10090; Drug Addresses Market Need for Long-Acting Treatment of Inflammation Post Cataract Surgery

Jun 22, 2014

Clarus Therapeutics Presents Phase 3 Data for REXTORO(R) for Men With Hypogonadism

Jun 15, 2014

Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes

May 28, 2014

Clarus Therapeutics to Present Phase 3 Data for REXTORO(R) at ICE/ENDO 2014

Apr 1, 2014

Intarcia Secures Second Landmark Private Financing of $200 Million - Strengthens Position To Complete Phase 3, Prepare For Launch, and Build Pipeline

Mar 19, 2014

Emmaus Life Sciences Announces Positive Top-Line Results Of Its Phase 3 Clinical Trial For Sickle Cell Disease

Jan 13, 2014

Intarcia CEO To Present Company Progress, Interim Phase 3 Data, And Key Milestones At J.P. Morgan

Oct 29, 2013

Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain

Sep 19, 2013

TauRx achieves milestone in global Phase 3 clinical trials of LMTX™ for Alzheimer's Disease

Aug 27, 2013

Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy

Apr 18, 2013

Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug

Mar 21, 2013

Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

Jan 28, 2013

Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial

Jan 28, 2013

Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial Deutschland - Deutsch España - español France - Français USA - English

Nov 15, 2012

Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes

Oct 30, 2012

Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Oct 3, 2012

Intarcia Announces Presentation of Analysis Used for Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

Sep 28, 2012

Intarcia to Present Analysis of Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

Sep 25, 2012

Clarus Therapeutics Top-line Results Show Oral Testosterone Replacement Candidate, CLR-610, Meets Phase 3 Study Primary Efficacy Endpoint

May 1, 2012

Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of its Proprietary Oral Testosterone Replacement Therapy

Apr 24, 2012

Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012

Apr 12, 2012

Tioga Pharmaceuticals Raises $10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome

Mar 27, 2012

Intarcia Appoints Michelle Baron, MD, FACE, Vice President and Chief Medical Officer

Feb 17, 2012

Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl and Agreement of the Phase 3 Program

Nov 10, 2011

Veloxis Pharmaceuticals Presents LCP-Tacro™ Phase 3 Data at the American Society of Nephrology Annual Meeting

Sep 14, 2011

Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon

Jun 28, 2011

Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions

Sep 22, 2010

Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD

Jun 3, 2010

Tioga Pharmaceuticals Begins Phase 3 Trial of Asimadoline in Irritable Bowel Syndrome

Apr 5, 2010

Tioga Pharmaceuticals Receives Special Protocol Assessment Agreement From FDA for Phase 3 Trials of Asimadoline in Irritable Bowel Syndrome

Feb 17, 2010

Tioga Pharmaceuticals, Inc. Raises $18 Million to Fund Phase 3 Clinical Trial in Irritable Bowel Syndrome